Premium
Decreased density of CD 3+ tumor‐infiltrating lymphocytes during gastric cancer progression
Author(s) -
Arigami Takaaki,
Uenosono Yoshikazu,
Ishigami Sumiya,
Matsushita Daisuke,
Hirahara Tetsushi,
Yanagita Shigehiro,
Okumura Hiroshi,
Uchikado Yasuto,
Nakajo Akihiro,
Kijima Yuko,
Natsugoe Shoji
Publication year - 2014
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.12551
Subject(s) - medicine , tumor infiltrating lymphocytes , cancer , immunosurveillance , tumor progression , adenoma , metastasis , gastroenterology , pathology , cancer research , immunotherapy
Background and Aim Tumor cells escape host immunosurveillance and thus produce an advantageous environment for tumor progression. Recent studies have demonstrated that tumor‐infiltrating lymphocytes ( TIL s) play a principal role in the immune response to tumors. However, little is understood about numerical alterations in CD 3+ TIL s during tumor progression in patients with gastric cancer. The present study examines the density of CD 3+ TIL s to elucidate their clinical significance in gastric cancer. Methods The numbers of CD 3+ TIL s in 120 resected specimens from patients with gastric cancer and 27 endoscopic resected specimens from patients with gastric adenoma were immunohistochemically assessed using a CD 3 polyclonal antibody. Results The mean number of CD 3+ TIL s (± SD ) in the patients with gastric cancer and adenoma was 87.5 ± 59.8 and 379.6 ± 128.1, respectively. Significantly more CD 3+ TIL s were found in specimens from patients with gastric adenoma than with gastric cancer ( P < 0.0001). The numbers of CD 3+ TIL s significantly correlated with depth of tumor invasion, lymph node metastasis, and stage ( P = 0.022, P = 0.0004, and P = 0.011, respectively). The 5‐year survival rate was significantly poorer for patients with fewer CD 3+ TIL s ( P = 0.004). Multivariate analysis selected the density of CD 3+ TIL s as an independent prognostic factor ( P = 0.034). Conclusions Our results demonstrated that the density of CD 3+ TIL s decreases during tumor progression. The density of CD 3+ TIL s is an immunological predictor of lymph node metastasis and disease outcome in patients with gastric cancer.